文献速递骨软组织肉瘤与黑色素瘤

患者来源的孤立性纤维性肿瘤异种移植模型预测多柔比星/达卡巴嗪联合方案高敏感性并在临床得到证实,同时凸显曲贝替定或艾日布林对该肿瘤的潜在有效性

Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.
PubMed 文献 · Eur J Cancer · 2017-03-08

研究建立两例去分化孤立性纤维性肿瘤(D-SFT)患者来源异种移植(PDX)模型并测试多柔比星、达卡巴嗪(DTIC)、异环磷酰胺、曲贝替定和艾日布林的抗肿瘤活性。多柔比星/DTIC联合在两个模型中最大肿瘤体积抑制均>80%,12例SFT患者回顾性分析显示最佳RECIST反应为6例缓解、1例稳定、5例进展,中位无进展生存6个月(M-SFT=6个月,D-SFT=10个月)。PDX对曲贝替定和艾日布林高度敏感。

要点

  • 多柔比星/DTIC联合在两个D-SFT PDX模型中最大肿瘤体积抑制均>80%。
  • 12例SFT患者中最佳RECIST反应为6例缓解、1例稳定、5例进展。
  • PDX对曲贝替定和艾日布林高度敏感,为D-SFT患者测试这些药物提供依据。

核心结论

  • 多柔比星联合DTIC在两个D-SFT小鼠模型中有效,在临床中似乎也有活性,尤其在高级别D-SFT患者中。
  • 在PDX中测试的其他药物中,曲贝替定和艾日布林高度有效,为在D-SFT患者中测试这些药物提供合理性依据。

研究设计与样本

  • 从患者活检获得两个去分化-SFT(D-SFT)模型并在免疫缺陷小鼠中生长。
  • 在这些模型上测试多柔比星、达卡巴嗪(DTIC)、异环磷酰胺(单药或联合)、曲贝替定和艾日布林的抗肿瘤活性。
  • 12例SFT患者接受多柔比星和DTIC治疗,回顾性评估RECIST反应、无进展生存和总生存,区分恶性-SFT(M-SFT)和D-SFT。

主要发现

  • 开发并表征了两个D-SFT患者来源异种移植(PDX),为首个可用的SFT临床前体内模型。
  • 多柔比星/DTIC、DTIC/异环磷酰胺、多柔比星/异环磷酰胺联合方案一致诱导比单药更好的抗肿瘤活性。
  • 多柔比星/DTIC联合在两个模型中最大肿瘤体积抑制均>80%。
  • 多柔比星/DTIC联合在病例系列中也有活性,最佳RECIST反应:6例缓解(M-SFT=7例中2例,D-SFT=5例中4例),1例稳定疾病,5例进展,中位无进展生存6个月(M-SFT=6个月,D-SFT=10个月)。
  • PDX对曲贝替定和艾日布林非常敏感。

关键数值与推荐

  • 多柔比星/DTIC联合在两个D-SFT PDX模型中最大肿瘤体积抑制均>80%。
  • 12例SFT患者最佳RECIST反应:6例缓解(M-SFT=7例中2例,D-SFT=5例中4例),1例稳定疾病,5例进展。
  • 中位无进展生存6个月(M-SFT=6个月,D-SFT=10个月)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preclinical models that mimic pathological and molecular features of solitary fibrous tumour (SFT) represent an important tool to select effective regimes and novel compounds to be tested in the clinic. This study was aimed at developing two preclinical models of SFT, assessing their predictive value in the clinic and selecting potential novel effective treatments. MATERIAL AND METHODS: Two dedifferentiated-SFT (D-SFT) models obtained from patients' biopsies were grown in immunodeficient mice. The antitumour activity on these models of doxorubicin, dacarbazine (DTIC), ifosfamide (monotherapy or combination), trabectedin and eribulin was tested. Twelve SFT patients were treated with doxorubicin and DTIC. Response by RECIST, progression-free survival and overall survival were retrospectively evaluated, distinguishing malignant-SFT (M-SFT) and D-SFT. RESULTS: Two D-SFT patient-derived xenografts (PDXs) that represent the first available preclinical in vivo models of SFT were developed and characterised. Doxorubicin/DTIC, DTIC/ifosfamide, doxorubicin/ifosfamide combinations consistently induced better antitumour activity than the single-agents. Particularly, doxorubicin/DTIC combination caused a max tumour volume inhibition >80% in both models. Doxorubicin/DTIC combo showed activity also in the case-series. Best RECIST responses were: 6 responses (M-SFT = 2 of 7, D-SFT = 4 of 5), 1 stable disease, 5 progressions, with a 6-month median progression-free survival (M-SFT = 6, D-SFT = 10 months). The PDXs were very sensitive to trabectedin and eribulin. CONCLUSION: Doxorubicin plus DTIC combination was effective in our two D-SFT mice models and appeared to be active also in the clinic, especially in high-grade D-SFT patients. Among additional drugs tested in the PDXs, trabectedin and eribulin were highly effective, providing a rational to test these drugs in D-SFT patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Stacchiotti S, Saponara M, Frapolli R, et al. Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour. Eur J Cancer. 2017. PMID: 28284173. doi:10.1016/j.ejca.2017.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。